On October 25, 2021 Theseus Pharmaceuticals, Inc. (the "Company") reported that exercised their option to purchase an additional 1,171,990 shares of common stock from the Company (Press release, Theseus Pharmaceuticals, OCT 27, 2021, View Source [SID1234592030]). The partial exercise of the over-allotment option closed on October 27, 2021, resulting in additional gross proceeds to the Company of approximately $18.8 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. After giving effect to this partial exercise of the over-allotment option, the total number of shares of common stock sold by the Company in the initial public offering increased to 11,172,190 shares and total gross proceeds increased to approximately $178.8 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!